Musings from The Power List: Dajun Yang
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
-
1
Lisaftoclax was approved in China in July 2025 for chronic lymphocytic leukemia, marking a significant milestone in B-cell lymphoma treatment.
-
2
Ascentage Pharma's BTK protein degrader received FDA clearance, highlighting advancements in targeted protein degradation.
-
3
Small molecules, including oral therapies like olverembatinib, maintain advantages in patient adherence and quality of life.
-
4
Targeted protein degradation technology is advancing rapidly, with 28 candidates in clinical trials by mid-2025.
-
5
The future of drug development will blur the lines between small molecules and biologics, focusing on biology-driven therapy choices.
